Opens in a new tab
Thursday, 19 November 2026
EVIDENCE. INTERPRETED.
Pharmacally

Atopic Dermatitis

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Atopic Dermatitis

18 stories · every one Fact-Checked
Lynk Pharmaceuticals expands Simcere collaboration for zemprocitinib in atopic dermatitis.Health TidingsLynk Expands Simcere Deal for Zemprocitinib in Atopic DermatitisLynk Pharmaceuticals has expanded its commercialization partnership with Simcere to include zemprocitinib for moderate-to-severe atopic dermatitis in adults across Greater China.2 Nov 2026 · 3 min read
Fact-Checked
Sitryx SYX-5219 oral PKM2 modulator under investigation for atopic dermatitis, targeting inflammatory pathways involved in eczema severity and itch.Clinical TrialsSitryx Reports Early Improvements in Atopic Dermatitis With SYX-5219Sitryx Therapeutics reports preliminary Phase 1b findings for SYX-5219, an investigational oral PKM2 modulator, with placebo-adjusted improvements in eczema severity and itch after six weeks.14 Oct 2026 · 4 min read
Fact-Checked
Tilrekimig Phase 2 atopic dermatitis study showing skin clearance and EASI-75 responseClinical TrialsPfizer’s Tilrekimig Achieves EASI-75 Across Doses in Phase 2 Atopic Dermatitis StudyPfizer’s investigational trispecific antibody tilrekimig achieved the primary EASI-75 endpoint across all evaluated doses at Week 16 in a Phase 2 study of adults with moderate-to-severe atopic dermatitis.1 Oct 2026 · 4 min read
Fact-Checked
Zumilokibart Phase 2 APEX Part B results in moderate to severe atopic dermatitisClinical TrialsZumilokibart Phase 2 Results Show EASI-75 Benefit in Atopic DermatitisAbbVie reported positive Phase 2 APEX Part B results for investigational zumilokibart in moderate to severe atopic dermatitis, with all three dose regimens significantly improving EASI-75 versus placebo…30 Sep 2026 · 4 min read
Fact-Checked
Almirall lebrikizumab and tildrakizumab data presented at EADV 2026 for atopic dermatitis and psoriasisHealth TidingsAlmirall’s New Lebrikizumab and Tildrakizumab Data Highlight Long-Term Outcomes in Atopic Dermatitis and PsoriasisAlmirall is presenting new clinical and real-world evidence for lebrikizumab in atopic dermatitis and tildrakizumab in psoriasis at EADV 2026, including five-year ADlong and two-year POSITIVE findings.30 Sep 2026 · 3 min read
Fact-Checked
Nemluvio nemolizumab three-year ARCADIA data showing sustained improvements in atopic dermatitisClinical TrialsGalderma’s Nemluvio Shows Sustained Atopic Dermatitis Benefits in 3-Year ARCADIA DataGalderma reports three-year ARCADIA long-term extension data showing sustained improvements in skin lesions, itch, sleep disturbance and quality of life with Nemluvio in patients aged 12 years and…30 Sep 2026 · 4 min read
Fact-Checked
Evommune EVO756 oral MRGPRX2 antagonist Phase 2b atopic dermatitis trial and EVO301 IL-18BP fusion proteinClinical TrialsEvommune Discontinues EVO756 in Atopic Dermatitis After Earlier CSU SetbackEvommune’s oral MRGPRX2 antagonist EVO756 failed to meet efficacy endpoints in a Phase 2b trial of moderate-to-severe atopic dermatitis.9 Sep 2026 · 3 min read
Fact-Checked
Rezpegaldesleukin Phase 2b REZOLVE-AD trial results in moderate-to-severe atopic dermatitisClinical TrialsRezpegaldesleukin Delivers Positive Phase 2b Results in Atopic Dermatitis, Supporting T-Reg ModulationNektar Therapeutics’ rezpegaldesleukin met the primary and key secondary endpoints in the Phase 2b REZOLVE-AD trial in moderate-to-severe atopic dermatitis, with the 24 μg/kg every-two-weeks regimen delivering a…25 Aug 2026 · 3 min read
Fact-Checked
Opzelura (ruxolitinib) cream receives positive CHMP opinion for adults with moderate atopic dermatitis in the European Union.Health TidingsEuropean Commission Approves Opzelura for Adults with Moderate Atopic Dermatitis After Inadequate Response to Standard Topical TherapiesThe European Commission has approved Opzelura (ruxolitinib) cream for adults with moderate atopic dermatitis who have an inadequate response or cannot use topical corticosteroids and calcineurin inhibitors.30 Jul 2026 · 4 min read
Fact-Checked
Opzelura (ruxolitinib) cream receives positive CHMP opinion for adults with moderate atopic dermatitis in the European Union.Clinical TrialsOrganon Reports Positive Phase 3 VTAMA Data in Atopic DermatitisOrganon presented the first age-stratified pooled Phase 3 ADORING trial analysis at SPD 2026, showing that VTAMA (tapinarof) cream achieved early and consistent improvements in skin clearance and…27 Jul 2026 · 4 min read
Fact-Checked
Illustration of InnoCare Pharma's oral TYK2 inhibitor soficitinib (ICP-332) achieving the primary endpoint in a Phase III trial for moderate-to-severe atopic dermatitis.Clinical TrialsInnoCare’s Soficitinib Meets Phase III Endpoint in Atopic DermatitisInnoCare Pharma announced positive topline results from its registrational Phase III trial of soficitinib (ICP-332) in moderate-to-severe atopic dermatitis.18 Jul 2026 · 4 min read
Fact-Checked
Gemini_Generated_Image_r10czbr10czbr10cClinical TrialsLEO Pharma Reports Positive Phase II TRAPEDS-1 Data Supporting Long-Term Safety of Tralokinumab in Children with Atopic DermatitisLEO Pharma announced positive topline results from the Phase II TRAPEDS-1 trial of tralokinumab in children aged 6–11 years with moderate-to-severe atopic dermatitis.10 Jul 2026 · 4 min read
Fact-Checked
Page 1 of 2